Testing of the Akt/PKB Inhibitor MK-2206 by the Pediatric Preclinical Testing Program

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2011 Nov 22

PMID 22102563

Citations 28

Authors

Richard Gorlick

John M Maris

Peter J Houghton

Richard Lock

Hernan Carol

Raushan T Kurmasheva

E Anders Kolb

Stephen T Keir

C Patrick Reynolds

Min H Kang

Catherine A Billups

Malcolm A Smith

Affiliations

Soon will be listed here.

Abstract

Background: MK-2206 is a small molecule allosteric inhibitor of Akt/PKB that is undergoing clinical trials for treatment of cancer.

Procedures: MK-2206 was tested against the PPTP in vitro panel using a 96-hour exposure (1.0 nM-10 µM), and in vivo using thrice weekly dosing for a planned 4 weeks at its maximum tolerated dose (MTD) of 180 mg/kg.

Results: In vitro, the median relative IC(50) value for MK-2206 was 2.2 µM. Four cell lines with IC(50) values < 200 nM included two ALL cell lines (COG-LL-317 and RS4;11), an AML cell line with an activating KIT mutation (Kasumi-1), and a Ewing sarcoma cell line (CHLA-10). In vivo, MK-2206 induced significant differences in EFS distribution compared to control in 12 of 29 (41%) of the evaluable solid tumor xenografts and in 2 of 8 (25%) of the evaluable ALL xenografts. Significant differences in EFS distribution were most frequently noted in the osteosarcoma panel (6 of 6). A single solid tumor xenograft (OS-31) had a greater than twofold increase in time to event compared to control animals, with all other solid tumor xenografts showing lesser degrees of tumor growth inhibition. Objective responses were not observed for either the solid tumor or ALL xenografts.

Conclusions: MK-2206 showed its most consistent activity in vitro against ALL cell lines and in vivo against osteosarcoma xenografts. However, no objective responses were observed in solid tumor or ALL xenografts. Further preclinical work evaluating MK-2206 in pediatric models in the combination therapy setting may contribute to its pediatric development.

Citing Articles

The Essential Oil from (L.) Cronquist (Asteraceae) Exerts an In Vitro Antimelanoma Effect by Inducing Apoptosis and Modulating the MAPKs, NF-κB, and PKB/AKT Signaling Pathways.

Ferreira R, Sousa Duarte S, Sousa V, de Souza R, Marques K, de Abrantes R Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004419 PMC: 10674350. DOI: 10.3390/ph16111553.

Investigating the Role of TGF-β Signaling Pathways in Human Corneal Endothelial Cell Primary Culture.

Aouimeur I, Sagnial T, Coulomb L, Maurin C, Thomas J, Forestier P Cells. 2023; 12(12).

PMID: 37371094 PMC: 10297110. DOI: 10.3390/cells12121624.

Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.

Candido M, Medeiros M, Veronez L, Bastos D, Oliveira K, Pezuk J Pharmaceutics. 2023; 15(2).

PMID: 36839989 PMC: 9966033. DOI: 10.3390/pharmaceutics15020664.

Evaluating the Effects of Separate and Concomitant Use of MK-2206 and Salinomycin on Prostate Cancer Cell Line.

Savaee M, Bakhshi A, Yaghoubi F, Pourrajab F, Goodarzvand Chegini K Rep Biochem Mol Biol. 2022; 11(1):157-165.

PMID: 35765523 PMC: 9208569. DOI: 10.52547/rbmb.11.1.157.

The NF-κB pathway is critically implicated in the oncogenic phenotype of human osteosarcoma cells.

Tan B, Yuan Z, Zhang Q, Xiqiang X, Dong J J Appl Biomed. 2021; 19(4):190-201.

PMID: 34907738 DOI: 10.32725/jab.2021.021.

References

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

Defeo-Jones D, Barnett S, Fu S, Hancock P, Haskell K, Leander K . Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther. 2005; 4(2):271-9. View

Kurmasheva R, Harwood F, Houghton P . Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther. 2007; 6(5):1620-8. DOI: 10.1158/1535-7163.MCT-06-0646. View

Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K . MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010; 9(7):1956-67. DOI: 10.1158/1535-7163.MCT-09-1012. View

Wendel H, de Stanchina E, Fridman J, Malina A, Ray S, Kogan S . Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004; 428(6980):332-7. DOI: 10.1038/nature02369. View

Larizza L, Magnani I, Beghini A . The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma. 2004; 46(2):247-55. DOI: 10.1080/10428190400007565. View

Osaki M, Oshimura M, Ito H . PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004; 9(6):667-76. DOI: 10.1023/B:APPT.0000045801.15585.dd. View

Meng J, Dai B, Fang B, Bekele B, Bornmann W, Sun D . Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One. 2010; 5(11):e14124. PMC: 2993951. DOI: 10.1371/journal.pone.0014124. View

Kim D, Dan H, Park S, Yang L, Liu Q, Kaneko S . AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci. 2004; 10:975-87. DOI: 10.2741/1592. View

10.

Kim B, van Golen C, Feldman E . Insulin-like growth factor I induces preferential degradation of insulin receptor substrate-2 through the phosphatidylinositol 3-kinase pathway in human neuroblastoma cells. Endocrinology. 2005; 146(12):5350-7. DOI: 10.1210/en.2005-0356. View

11.

Silva A, Yunes J, Cardoso B, Martins L, Jotta P, Abecasis M . PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest. 2008; 118(11):3762-74. PMC: 2556239. DOI: 10.1172/JCI34616. View

12.

Scotlandi K, Manara M, Nicoletti G, Lollini P, Lukas S, Benini S . Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 2005; 65(9):3868-76. DOI: 10.1158/0008-5472.CAN-04-3192. View

13.

Ho R, Eggert A, Hishiki T, Minturn J, Ikegaki N, Foster P . Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res. 2002; 62(22):6462-6. View

14.

Kolb E, Gorlick R, Houghton P, Morton C, Lock R, Carol H . Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008; 50(6):1190-7. DOI: 10.1002/pbc.21450. View

15.

Witzig T, Kaufmann S . Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol. 2006; 7(4):285-94. DOI: 10.1007/s11864-006-0038-1. View

16.

Brazil D, Hemmings B . Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci. 2001; 26(11):657-64. DOI: 10.1016/s0968-0004(01)01958-2. View

17.

Opel D, Poremba C, Simon T, Debatin K, Fulda S . Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res. 2007; 67(2):735-45. DOI: 10.1158/0008-5472.CAN-06-2201. View

18.

Kang M, Smith M, Morton C, Keshelava N, Houghton P, Reynolds C . National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer. 2010; 56(2):239-49. PMC: 3005554. DOI: 10.1002/pbc.22801. View

19.

Bellacosa A, Kumar C, Di Cristofano A, Testa J . Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005; 94:29-86. DOI: 10.1016/S0065-230X(05)94002-5. View

20.

Jaboin J, Kim C, Kaplan D, Thiele C . Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway. Cancer Res. 2002; 62(22):6756-63. View